Pilot study of safety and effect of combined intravitreal bevacizumab and methotrexate for neovascular age-related macular degeneration

European Journal of Ophthalmology

Volumn 21, Issue 1, 2011, Pages 77-82

  Soheilian, Masoud ^a,b   Movaseghi, Mehryar ^a   Ramezani, Alireza ^a,b   Peyman, Gholam A ^c,d  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Negah Eye Hospital   (Iran)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

Age related macular degeneration; Bevacizumab; Choroidal neovascularization; Methotrexate

Indexed keywords

BEVACIZUMAB; EBETREX; METHOTREXATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORNEA DISEASE; CORNEAL EPITHELIOPATHY; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MALE; OPTIC NERVE ATROPHY; PILOT STUDY; PRIORITY JOURNAL; REMISSION; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; METHOTREXATE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; RETREATMENT; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 78650680555     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/EJO.2010.5696     Document Type: Article

References (36)

1. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of agerelated macular degeneration in the United States. Arch Ophthalmol 2004; 122: 564-72.
2. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004; 122: 477-85.
3. Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 1998; 116: 653-8.
4. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003; 22: 1-29.
5. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005; 25: 111-8.
6. Otani A, Takagi H, Oh H, Koyama S, Matsumura M, Honda Y. Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1999; 40: 1912-20.
7. Holekamp NM, Bouck N, Volpert O. Pigment epithelium-derived factor is deficient in vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am J Ophthalmol 2002; 134: 220-7.
8. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-16.
9. Rosenfeld PJ, Brown DM, Herier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31.
10. Bashshur ZF, Bazarbachi AM, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 142: 1-9.
11. Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment-TAP and VIP report no. 2. Arch Ophthalmol 2003; 121: 1253-68.
12. Lux A, Llacer H, Heussen FM, Joussen AM. Non responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 2007; 91: 1318-22.
13. Wong VG, Hersh EM, McMaster PR. Treatment of a presumed case of sympathetic ophthalmia with methotrexate. Arch Ophthalmol 1966; 76: 66-76.
14. Martenet AC. [Failures of cytostatic treatment in ophthalmology (author's trans)] [French]. Klin Monatsbl Augenheilkd 1980; 176: 648-51.
15. Egan LJ, Sandborn WJ. Methotrexate for inflammatory bowl disease: pharmacology and preliminary results. Mayo Clin Proc 1996; 71: 69-80.
16. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001; 20: 705-32.
17. Donoso LA, Kim D, Frost A, Callahan A, Hageman G. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2006; 51: 137-52.
18. Huang CC, Hsu PC, Hung YC, et al. Ornithine decarboxylase prevents methotrexate-induced apoptosis by reducing intracellular reactive oxygen species production. Apoptosis 2005; 10: 895-907.
19. Hsu PC, Hour TC, Liao YF, et al. Increasing ornithine decarboxylase activity is another way of prolactin preventing methotrexate-induced apoptosis: crosstalk between ODC and BCL-2. Apoptosis 2006; 11: 389-99.
20. Winter-Vann AM, Kamen BA, Bergo MO, et al. Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate. Proc Natl Acad Sci USA 2003; 100: 6529-34.
21. Fiehn C, Wunder A, Krienke S, Max R, Ho AD, Moehler T. Lack of evidence for inhibition of angiogenesis as a central mechanism of the antiarthritic effect of methotrexate. Rheumatol Int 2005; 25: 108-13.
22. Kusabe T, Waguri-Nagaya Y, Tanikawa T, et al. The inhibitory effect of disease-modifying anti-rheumatic drugs and steroids on gliostatin/platelet- derived endothelial cell growth factor production in human fibroblast-like synoviocytes. Rheumatol Int 2005; 25: 625-30.
23. Solomon S, Masilamani M, Mohanty S, Schwab JE, Boneberg EM, Illges H. Generation of three-dimensional pannus-like tissues in vitro from single cell suspensions of synovial fluid cells from arthritis patients. Rheumatol Int 2004; 24: 71-6.
24. Haskó G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004; 25: 33-9.
25. de Lathouder S, Gerards AH, Dijkmans BA, Aarden LA. Two inhibitors of DNA-synthesis lead to inhibition of cytokine production via a different mechanism. Nucleosides Nucleotides Nucleic Acids 2004; 23: 1089-100.
26. Kraan MC, Smeets TJM, van Loon MJ, Breedveld FC, Dijkmans BA, Tak PP. Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Ann Rheum Dis 2004; 63: 1056-61.
27. Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H. The anti- inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005; 114: 154-63.
28. Frenkel S, Hendler K, Siegal T, Shalom E, Pe'er J. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol 2008; 92: 383-8.
29. Gerards AH, de Lathouder S, de Groot ER, Dijkmans BA, Aarden LA. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology 2003; 42: 1189-96.
30. Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology 2009; 116: 797-801.
31. Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001; 108: 1134-9.
32. Hardwig PW, Pulido JS, Erie JC, Baratz KH, Buettner H. Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma. Am J Ophthalmol 2006; 142: 883-5.
33. Haskó G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004; 25: 33-9.
34. Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor A in patients with choroidal neovascularization. Ophthalmology 2008; 115: 1750-5.
35. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005; 57: 163-72.
36. Green WR. Histopathology of age-related macular degeneration. Mol Vis 1999; 5: 27.